Event Date: 20200615 – 20201231
Potential carcinogens N-nitrosamines continue to keep pharmaceutical companies in the crosshairs of health regulators. At every stage of the production process, regulators are demanding increased scrutiny on the presence of nitrosamine and a suite of robust, cost effective techniques are desperately needed to face this issue. The automation that we at Anatune specialise in offers the best chance of meeting the data quality and required throughput.
At this forum, senior scientists from major pharmaceutical companies are coming together to collaborate and solve this problem as quickly as possible. If you work in the pharmaceutical industry or have any interest in the measurement of nitrosamines, this event is for you.
00:00:00- Introduction: Dan Carrier, Anatune
00:05:00 – Regulatory Considerations for Nitrosamine Analysis – Andrew Teasdale AstraZeneca
00:38:40 – The challenge of nitrosamines in drug products and API: how automation can help – Camilla Liscio, Anatune
01:00:00 – Q&A
01:09:00 – Comparison of OMCL Methods for Nitrosamine Impurities in Sartans and Recent Analysis – Mark Harrison, AstraZeneca
01:36:25 – Nitrosamine Analysis with CROs – Tony Taylor, Arch Sciences Group
02:01:00 – Q&A and final discussion.